Ironwood starts IBS trial in China, but stock falls on analyst forecast
September 11, 2013 at 13:55 PM EDT
Ironwood Pharmaceuticals Inc. (Nasdaq: IRWD) has announced a late-stage trial in China seeking to get its irritable bowel syndrome (IBS) drug approved there, but lost 4 percent of stock value after an analyst firm lowered his price target...